Table 1.
Clinical Characteristics of COVID-19 Patients Undergoing Percutaneous Dilational Tracheostomy
| Variable | PDT Patients (n = 98) |
|---|---|
| Sex | |
| Male | 80 (82) |
| Female | 18 (18) |
| Age, y | 57 ± 15 |
| Body mass index, kg/m2 | 31 ± 6 |
| Comorbidities | |
| Cardiaca | 43 (44) |
| Diabetes mellitus | 30 (31) |
| Asthma/COPD | 3 (3) |
| Chronic kidney disease | 9 (9) |
| Stroke | 6 (6) |
| HIV/AIDS | 3 (3) |
| MV and oxygenation values | |
| Plateau pressure | 26 ± 6 |
| Positive end expiratory pressure | 12 ± 4 |
| Pao2/Fio2 ratio | 132 ± 58 |
| Deep sedation and paralysis | 56 (57) |
| Days on ventilator before tracheostomy | 11 ± 5 |
| Follow-up after starting MV, d | 18 ± 5 |
| Follow-up after PDT, d | 11 ± 6 |
Values are n (%) or mean ± SD.
COPD, chronic obstructive pulmonary disease; Fio2, fraction of inspired oxygen; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; MV, mechanical ventilation; PDT, percutaneous dilational tracheostomy.
a
Includes coronary artery disease and hypertension.